抄録
Introduction
Biologics have remarkable curative effects on rheumatoid arthritis (RA).
Tocilizmab was approved on April 16, 2008, and the administration of the preparation began at our clinic in May.
The clinical progress of tocilizmab has not been examined. We would like to report observations of cases of RA with tocilizmab made by physical therapists.
Object
Two male and seven female patients (mean age of nine cases: 61.2 years).
Method
The transition of numerical values of CRP and DAS28 was examined for 12 weeks immediately after tocilizmab was administered. The measurement of swelling of joints numerical values of VAS and measurement of joint motion were examined for the same period.
Clinical results
The tocilizmab improved the numerical value of CRP remarkably in a week.
It improved DAS28 gradually.
Eight weeks later than the change in CRP and DAS28, swelling of joints was improved.
12 weeks later than the change in CRP, VAS was improved.
ROM was not improved.
Consideration and conclusion
The curative effects of tocilizmab include remarkable improvement of the numerical value of CRP in a week, slow improvement of measurement of swelling of joints and VAS.ROM was not improved.
Therefore, the clinical progress of tocilizmab seems to be different from other biologics.
We conclude that satisfaction of the patient is obtained12weeks after administration of tocilizmab.
